AVVA’s Antibiotics Safety Project aims to the development of antibiotics that will have improved safety and efficacy profiles and relieve the economic burden associated with the safety profile of standard antibiotic treatments.

At AVVA we utilize our research and comprehension of the human microbiome and its impact on the host, and develop fixed dose combination products that either protect or enhance the activity of symbiotic bacteria.